[{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regencell Bioscience\u2019s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Regencell Bioscience"},{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Regencell Bioscience"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The results are consistent with earlier analysis announced showing RGC-COV19 (RGCA-CV01) is effective in reducing and eliminating COVID-19 symptoms within 6 days, which in turn reduces the risk of hospitalization and death.
36 out of 37 COVID-19 patients treated in the trial with RGC-COV19, representing approximately 97.3% of the patients, reported they had all symptoms eliminated within the 6-day treatment period save for loss or reduced sense of taste and smell and occasional cough.